Efficacy of S-1 in Patients with Castration-Resistant Prostate Cancer: A Phase II Study

Publisher： Karger

E-ISSN： 1423-0232|78|5-6|323-328

ISSN： 0030-2414

Source： Oncology, Vol.78, Iss.5-6, 2010-08, pp. : 323-328

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

High-Dose Calcitriol, Docetaxel and Zoledronic Acid in Patients with Castration-Resistant Prostate Cancer: A Phase II Study

By  

Urologia Internationalis, Vol. 90, Iss. 1, 2012-11 ,pp. : 56-61

Karger

Access to resources Recommend Favorite

The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study

By  

Oncology, Vol. 90, Iss. 2, 2016-0 ,pp. : 69-78

Karger

Access to resources Recommend Favorite

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer

By  

BJU INTERNATIONAL, Vol. 118, Iss. 4, 2016-10 ,pp. : 590-597

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and efficacy of 2‐weekly cabazitaxel in metastatic castration‐resistant prostate cancer

By  

BJU INTERNATIONAL, Vol. 121, Iss. 2, 2018-02 ,pp. : 203-208

John Wiley & Sons Inc

Access to resources Recommend Favorite

Everolimus combined with gefitinib in patients with metastatic castration‐resistant prostate cancer: Phase 1/2 results and signaling pathway implications

By  

CANCER, Vol. 121, Iss. 21, 2015-11 ,pp. : 3853-3861

John Wiley & Sons Inc

Access to resources Recommend Favorite